Study reveals novel mutations in mucosal melanoma that may pave way for new therapies
Can't see this email? View it online
   
  March 20, 2017  
  Skin Cancer  
  The latest skin cancer news from News Medical  
 Study reveals novel mutations in mucosal melanoma that may pave way for new therapiesStudy reveals novel mutations in mucosal melanoma that may pave way for new therapies
 
Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues.
 
 
 Drug combination delivered by nanoparticles may keep melanoma from becoming resistant to treatmentDrug combination delivered by nanoparticles may keep melanoma from becoming resistant to treatment
 
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers.
 
   Researchers identify key mutation that promotes melanoma growth by suppressing immune responseResearchers identify key mutation that promotes melanoma growth by suppressing immune response
 
University of California, Irvine researchers have identified a specific mutation that allows melanoma tumor cells to remain undetected by the immune system.
 
   New biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patientsNew biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patients
 
Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable.
 
   Targeting cancer stem cells may be effective way to prevent spread of squamous cell carcinomaTargeting cancer stem cells may be effective way to prevent spread of squamous cell carcinoma
 
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
 
 LJI researchers unravel molecular underpinnings of exhausted T cells
 
LJI researchers unravel molecular underpinnings of exhausted T cellsOne reason we survive into adulthood is that cell-killing T cells usually recognize and eliminate cancerous or pathogen-infected cells.
 
 
 Combination approach holds potential for treating lung cancer patients
 
Combination approach holds potential for treating lung cancer patientsAn emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.
 
 
 Evolution of immuno-oncology
 
Evolution of immuno-oncologyImmuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).